Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.
The MIND Foundation, a nonprofit mental health organization dedicated to psychedelic research and education, welcomes applications for the sixth course of its Augmented Psychotherapy Training (APT), a 15-month program that provides healthcare professionals with the knowledge and skills required to practice psychedelic therapy in a legal, safe, and evidence-based framework.
We share the first in a series of dispatches from Jack Gorsline, a journalist who is quite literally ‘on the ground’ in the heart of this election season’s psychedelic policy reform battleground: Massachusetts.
BioSpace speaks to three experts, including Cybin CEO Doug Drysdale, about Mass. Question 4.
TOOLS FOR TEACHERS
Our friends at BrainFutures have published a toolkit for academic leaders who are interested in integrating psychedelic coursework into higher education.
A new named professorship supports Deepak Cyril D’Souza’s research on the potential for psychedelic drugs to treat post-traumatic stress disorder and depression.
UCLA’s Ecological Medicine & Psychedelic Studies Initiative is hosting a one-day hybrid event that aims to bridge mental health, Indigenous perspectives, legal rights, city planning, ethnobotany, conservation, ecology, and psychedelic therapies… gosh! Free to attend.
Vicente LLP looks at big-picture questions as the program hurtles towards launch. First up are fees and rule changes, before the firm reviews Natural Medicine-related meetings since our last Bulletin in late August.
Shayla Love explores how “new, non-hallucinogenic versions of psychedelics are blurring the boundaries of the drug trip. (* Included here as it just missed the cut-off for last week’s Feed.)
SEE YOU THERE?
Psychedelic Alpha is pleased to be a sponsor of this year’s UW Madison Psychedelic Symposium. We hope to see you there.
Next year’s track includes around twenty psychedelics-related panels or presentations, including a panel discussion titled ‘Behind the Scenes of the “Psychedelic Renaissance”‘ that sees our Editor Josh Hardman joined by The Microdose’s Jane Hu, The Atlantic’s Shayla Love, and Calyx Law’s Graham Pechenik (who is also an Editor-at-Large here at Psychedelic Alpha).
Our friends at PsyMed Ventures have teamed up with KdT Ventures to offer a virtual workshop for scientists who want to build a neuroscience startup.
If you’ve had personal experience with classic psychedelics—such as LSD, psilocybin, ayahuasca, DMT, or mescaline—you are invited to take part. The survey takes approximately 30 minutes to complete and is best experienced on a computer or in landscape mode on a mobile device.
The MIND Foundation, a nonprofit mental health organization dedicated to psychedelic research and education, welcomes applications for the sixth course of its Augmented Psychotherapy Training (APT), a 15-month program that provides healthcare professionals with the knowledge and skills required to practice psychedelic therapy in a legal, safe, and evidence-based framework.
Bessel van der Kolk encourages Massachusetts voters to get approve the psychedelics question this November.
Lykos Therapeutics has provided an update on a recent meeting with the FDA re: its MDMA for PTSD New Drug Application. The very brief 100-word statement reveals that the ‘path forward’ for the program will include an additional Phase 3 trial, but could also entail an independent, third-party review of the two existing Phase 3 studies (MAPP1 and MAPP2).
Host Regina G. Barber talks with Rosalyn LaPier about ethnobotany–what it is and how traditional plant knowledge is frequently misunderstood in the era of COVID and psychedelics.
“To develop the new drugs, Castrén and his coworkers have established a company called Kasvu Therapeutics. He has received financial support from University of Helsinki Funds, which has also helped him develop the company.”
THE FIGHT FOR QUESTION 4 IN MASSACHUSETTS
As the U.S. elections draw closer coverage of Massachusetts’ Question 4 is heating up, too. If voters endorse the ballot question the state would be tasked with decriminalising certain naturally-occurring psychedelics and establishing a regulated program similar to Oregon’s. But polling shows that the vote is currently too close to call, with donors pouring last-minute funding into the Yes campaign (See Bulletin 176 for more).
We spoke with Massachusetts Psychiatry Society president Nassir Ghaemi about why his group is opposing Question 4, as well as his broader views on psychedelics.
The Boston Globe’s editorial board shares their reasons for opposing the initiative.
The Globe also ran more of an explainer piece, which includes the testimony of a retired school teacher who found psilocybin to be beneficial to her trauma and depression.
The Herald speaks to the initiative’s supporters.
Some local councils in Mass. are taking positions on the Question, too, or at least hosting hearings.
CIIS to launch the first-ever undergraduate Bachelor of Science in Psychedelic Studies offering, planned to begin in fall 2025.
This free, hybrid (in-person and virtual) conference will feature multidisciplinary discussions from the likes of Eduardo Schenberg, Katherine Hendy, Claudia Schwartz and Franklin King.
Ft. Mindstate Design Labs, Beckley Psytech, atai Life Sciences, MindMed, Gilgamesh Pharmaceuticals, Enveric Biosciences.
Free subscribers receive a weekly round-up of news on psychedelics, as well as the occasional article.
Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.
Teams, groups and corporate pricing plans are available, please get in touch via email to learn more.
Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete archive and Library.
Learn More| Free | ||
|---|---|---|
| Weekly Psychedelic News Feed | ||
| Occasional Articles & Free Resources | ||
| Psychedelic Bulletins (In-Depth Briefings, Multiple per Month) | ||
| Quick-Take Analysis of Major Developments | ||
| In-Depth Articles & Deep Dives | ||
| Exclusive Interviews with Insiders & KOLs | ||
| Quarterly Video Briefings | ||
| Exclusive Tools & Data Resources | ||
| Library of Primers & Explainers | ||
|
Subscribe Now |
||
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.